Combination of Topiramate(Conviban) and Empagliflozin(Jardiance) is Considered a Good Option for the Treatment of Obesity
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- change in weight
研究概览
简要总结
The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group).
.
详细描述
The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group).
Materials and methods 200 obese patients 4 groups. had been monitored in a private clinic, each group 50 patients number, with 35 females and 15 males who were already on treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •stable weight in the previous 6 months.
- •a sedentary lifestyle.
- •no history of diabetes mellitus.
- •taking medication that affects appetite, or weight within the past 6 months
排除标准
- •severe anemia
- •hypothyroidism and hyperthyroidism
- •Diabetes mellitus
- •moderate to severe liver or kidney disease
- •body mass index less than 30
研究组 & 干预措施
on topiramate
"topiramate", "conviban®" group vs no treatment ( control group).
干预措施: The intervention being studied (Drug)
on empagliflozine
"empagliflozine", "jardiance®" vs no treatment ( control group).
干预措施: The intervention being studied (Drug)
on topiramate plus empagliflozine
all patients' vs no treatment ( control group).
干预措施: The intervention being studied (Drug)
no treatment
all patients' vs no treatment ( control group).
干预措施: The intervention being studied (Drug)
结局指标
主要结局
change in weight
时间窗: 6 months
weight measurement
次要结局
未报告次要终点
研究者
mahmoud younis
Principal Investigator
Cairo University